

CITATION REPORT

List of articles citing

Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19

DOI: 10.1016/j.medj.2020.06.001
Med, 2020, 1, 114-127.e3.

Source: <https://exaly.com/paper-pdf/76877517/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
362	Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era. 2020 , 13, e008937		9
361	Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art. 2020 , 11, 577442		16
360	Pharmacological Advances of Chloroquine and Hydroxychloroquine: From Antimalarials to Investigative Therapies in COVID-19. 2020 , 15, 1934578X2095364		1
359	Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. 2020 , 31, 2475-2489		6
358	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. 2020 , 80, 1929-1946		45
357	Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond. 2020 , 28, 2040206620961712		12
356	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. 2020 , 216, 107672		31
355	Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10 131 US Veterans With SARS-CoV-2 Infection. 2020 , 3, e2022310		158
354	COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic. 2020 , 261, 118336		35
353	Therapeutic options for the management of severe COVID-19: A rheumatology perspective. 2021 , 17, 431-436		1
352	The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis. 2020 , 2020, 4312519		16
351	Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment. 2020 , 11, 570063		8
350	A stance data set on polarized conversations on Twitter about the efficacy of hydroxychloroquine as a treatment for COVID-19. 2020 , 33, 106401		9
349	A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. 2020 , 11, 5284		45
348	Double Jeopardy Cardiomyopathy Requiring Heart Transplant: Hydroxychloroquine and Rheumatoid Arthritis. 2020 , 4, 382-385		0
347	[Treatment of Sars-Cov2 with hydroxychloroquine is ineffective and potentially harmful]. 2020 , 2020, 25-27		0
346	A quantitative framework for exploring exit strategies from the COVID-19 lockdown. 2020 , 140, 110244		18

345	Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. 2020 , 2, 1-23	45
344	Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?. 2020 , 6, e04900	9
343	Peptides: Prospects for Use in the Treatment of COVID-19. 2020 , 25,	13
342	Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review. 2020 , 38, 100776	20
341	Repurposing Existing Drugs for the Treatment of COVID-19. 2020 , 17, 1186-1194	15
340	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. 2020 , 59, 176-190	44
339	The Cardiovascular Effects of Treatment with Hydroxychloroquine and Azithromycin. 2020 , 40, 978-983	4
338	Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. 2020 , 2, 1-12	11
337	Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center. 2020 , 35, 1250-1261	49
336	High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects. 2020 , 11, 1660	28
335	In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. 2020 , 181, 104878	70
334	Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. 2020 , 56, 106101	52
333	Safety perspectives on presently considered drugs for the treatment of COVID-19. 2020 , 177, 4353-4374	9
332	The dynamic treatment of SARS-CoV-2 disease. 2020 , 33, 572-579	1
331	Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety. 2020 , 28, 1760-1776	14
330	Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science. 2020 , 34, 525-541	11
329	Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. 2020 , 27, 434-441	2
328	. 2020 , 192, E1585-E1596	2

327	Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial. 2021 , 199, 3642-3646		28
326	COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. 2020 , 45, 1		24
325	Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. 2020 , 173, W128-W129		12
324	Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. 2020 , 173, W156-W157		17
323	Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians. 2020 , 173, W48-W51		8
322	Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis. 2020 , 8,		4
321	Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. 2020 , 173, W78-W79		15
320	Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements. 2020 , 11, 559996		1
319	COVID-19: A review of the proposed pharmacological treatments. 2020 , 886, 173451		54
318	Comment on Arshad et al.: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19. <i>International Journal of Infectious Diseases</i> , 2020 , 99, 373	10.5	5
317	Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study. 2020 , 22, 842-844		11
316	Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?. 2020 , 28, 266-271		8
315	Emerging Therapeutic Modalities against COVID-19. 2020 , 13,		11
314	Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians. <i>American Journal of Emergency Medicine</i> , 2020 , 38, 2209-2217	2.9	21
313	Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. 2020 , 11, 1409		27
312	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. 2020 , 21,		27
311	Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. 2020 , 7, 482		22
310	COVID-19: a wreak havoc across the globe. 2020 , 1-13		2

309	Hydroxychloroquine Alternatives for Chronic Disease: Response to a Growing Shortage Amid the Global COVID-19 Pandemic. 2020 , 897190020942658	5
308	Searching for COVID-19 treatments: First, do no harm. 2020 , 77, 1899-1905	2
307	Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review. 2020 , 15, 350-358	17
306	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. 2020 , 26, 2181-2189	27
305	Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. 2020 , 26, 1436-1446	53
304	Chloroquine and hydroxychloroquine for COVID-19: time to close the chapter. 2021 , 97, 676-677	7
303	Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity. 2020 , 13, 439-452	26
302	Antimalarials as Antivirals for COVID-19: Believe it or Not!. <i>American Journal of the Medical Sciences</i> , 2020 , 360, 618-630	2.2 14
301	Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. 2020 , 26, 1537-1544	50
300	Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine. 2020 , 13, 531-542	5
299	COVID-19 and Cardiovascular Health Among Patients with Cancer. 2020 , 22, 171	5
298	Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. 2020 , 358, 104240	4
297	Current Options in the Treatment of COVID-19: A Review. 2020 , 13, 1999-2010	5
296	Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic. 2020 , 7, 562142	11
295	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. 2020 , 11, 562264	5
294	Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19?. 2020 , 12, 1139-1144	1
293	. 2020 , 192, E1323-E1333	
292	Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. 2020 , 11, 554172	4

291	Stopping the COVID-19 Pandemic: A Review on the Advances of Diagnosis, Treatment, and Control Measures. 2020 , 2020, 9121429	10
290	Observational study of azithromycin in hospitalized patients with COVID-19. <i>PLoS ONE</i> , 2020 , 15, e0238681	14
289	A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. 2020 , 2, 1-13	26
288	Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. 2020 , 35, 3308-3314	59
287	Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version). 2020 , 7, 41	37
286	Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. 2020 , 11, 2159	6
285	Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. 2020 , 585, 584-587	198
284	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview. 2020 , 78,	10
283	Balancing Scientific Rigor With Urgency in the Coronavirus Disease 2019 Pandemic. 2020 , 7, ofaa304	5
282	Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?. 2020 , 11, 1969	5
281	Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 Infection. 2020 , 9,	6
280	Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19. 2020 , 13, 1071-1076	22
279	Electrocardiographic Changes and Arrhythmias in Hospitalized Patients With COVID-19. 2020 , 13, e009023	6
278	Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19. 2020 , 42, 25	8
277	Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety. 2020 , 12, 115-121	1
276	Methodological Issues and Controversies in COVID-19 Coagulopathy: A Tale of Two Storms. 2020 , 26, 1076029620945398	3
275	It Takes a Village—Contending With Drug Shortages During Disasters. 2020 , 158, 2414-2424	11
274	Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review. 2020 , 37, 4107-4131	2

273	COVID-19 Therapeutic Options Under Investigation. 2020 , 11, 1196	49
272	Efficacy of various treatment modalities for nCOV-2019: A systematic review and meta-analysis. 2020 , 50, e13383	12
271	Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?. 2020 , 7,	10
270	Antitussive nospapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis. 2020 , 1-16	14
269	Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review. 2020 , 7, 2049936120947517	9
268	A Narrative Review of Emerging Therapeutics for COVID-19. 2020 , 4, 745-758	5
267	The plural of anecdote is not data, please mind the gap between virtual and real life. 2020 , 30, 732-733	2
266	A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. 2020 , 10, 22139	41
265	A systematic review assessing the under-representation of elderly adults in COVID-19 trials. 2020 , 20, 538	17
264	Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules. 2020 , 13,	12
263	A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. 2020 , 27, 493-504	78
262	Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 808-814	2.9 13
261	Drug repurposing against COVID-19: focus on anticancer agents. 2020 , 39, 86	44
260	The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway. 2020 , 179, 237-246	12
259	Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children's Hospital in New York City, New York. 2020 , 174, e202430	272
258	"Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.". 2020 , 14, 589-596	78
257	Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. 2020 , 63, 1515-1521	85
256	Potential negative effects of the free use of chloroquine to manage COVID-19 in Colombia. 2020 , 92, 2254-2256	3

255	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. 2020 , 395, 1907-1918	880
254	COVID-19 in rheumatic disease patients on immunosuppressive agents. 2020 , 50, 680-686	36
253	Navigating COVID-19 in the developing world. 2020 , 39, 2039-2042	4
252	Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. 2020 , 26, 979-987	33
251	Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. 2020 , 7, 1428-1436	48
250	IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?. 2020 , 34, 223-231	81
249	Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. 2020 , 132, 604-613	19
248	Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. 2020 , 192, E734-E744	51
247	Erythropoietin as candidate for supportive treatment of severe COVID-19. 2020 , 26, 58	26
246	COVID-19 research: pandemic "paperdemic", integrity, values and risks of the "speed science". 2020 , 5, 174-187	42
245	A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation. 2020 , 9,	16
244	Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend. 2020 , 81, e117-e119	8
243	Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. 2020 , 38, 100709	48
242	COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2. 2020 , 34, 1567-1588	57
241	Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences. 2020 , 38, 100710	6
240	Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19. <i>Med</i> , 2020 , 1, 114-127.e3	31.7 315
239	Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic. 2020 , 16, 314-320	7
238	Effects of hydroxychloroquine treatment on QT interval. 2020 , 17, 1930-1935	27

237	Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. <i>International Journal of Infectious Diseases</i> , 2020 , 97, 396-403	10.5	330
236	Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials. 2020 , 6, 1028-1031		5
235	COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). 2020 , 56, 106080		96
234	Clinical Trials of Repurposed Antivirals for SARS-CoV-2. 2020 , 64,		26
233	Canonical and Noncanonical Autophagy as Potential Targets for COVID-19. 2020 , 9,		34
232	Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. 2020 , 83, 1150-1159		13
231	Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae. 2020 , 61, 597-606		17
230	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. 2020 , 16, 659-666		40
229	Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. 2020 , 81, 919		17
228	Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk. 2020 , 17, 1480-1486		18
227	A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?. 2020 , 56, 106078		29
226	COVID-19: Immunology and treatment options. 2020 , 215, 108448		321
225	An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic. 2021 , 17, 2012-2017		16
224	Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. 2021 , 3, e19-e27		28
223	Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. 2021 , 890, 173717		14
222	Late onset infectious complications and safety of tocilizumab in the management of COVID-19. 2021 , 93, 1459-1464		38
221	Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned. 2021 , 29, 220-227		1
220	Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection. 2021 , 93, 775-785		11

219	Primed for global coronavirus pandemic: Emerging research and clinical outcome. 2021 , 209, 112862	10
218	Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. 2021 , 76, 30-42	70
217	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. 2021 , 72, e835-e843	59
216	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. 2021 , 17, 46-64	209
215	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. 2021 , 133, 111008	14
214	Re: effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: author's response. 2021 , 27, 920-921	11
213	Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. 2021 , 133, 110982	31
212	Clinical Characteristics and Outcomes in Patients with COVID-19 and Cancer: a Systematic Review and Meta-analysis. 2021 , 33, e180-e191	19
211	Protoporphyrin IX and verteporfin potentially inhibit SARS-CoV-2 infection and in a mouse model expressing human ACE2. 2021 , 66, 925-936	11
210	Taking a stand against the politicization of medical research: how 'swinging the pendulum' poses a hazard to clinical trials, study participants, and the progress of science. 2021 , 17, 101-103	1
209	A brief review on potential application of mesenchymal stem cell and secretome in combating mortality and morbidity in COVID-19 patients. 2021 , 44, 63-73	7
208	Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs. 2021 , 57, 106222	13
207	Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses. 2021 , 19, 1-15	11
206	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. 2021 , 53, 117-134	26
205	Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. 2021 , 27, 19-27	144
204	Azithromycin in the treatment of COVID-19: a review. 2021 , 19, 147-163	71
203	Immune response and possible therapeutics in COVID-19.. 2020 , 11, 960-977	2
202	COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. 2021 , 41, 257-273	0

201	Sialylation of host proteins as targetable risk factor for COVID-19 susceptibility and spreading: A hypothesis. 2021 , 3, 192-197		0
200	Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs. 2021 , 22, 59		8
199	Beyond the ventilator - cardiovascular management in SARS-CoV-2 infection. 2021 , 10, 43		
198	Development of Coronavirus Treatments Using Neutralizing Antibodies. <i>Microorganisms</i> , 2021 , 9,	4-9	3
197	Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery. 2021 , 17, 1538-1546	12	
196	Systematic review and meta-analysis of efficacy and safety of hydroxychloroquine and chloroquine in the treatment of COVID-19. 2021 , 10, 2126-2139		1
195	From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?. 2021 , 28,		11
194	Vaccines, Resource Allocation, and Unproven Treatments. 2021 , 151-174		
193	Examination of patient characteristics and hydroxychloroquine use based on the US Food and Drug Administration's recommendation: a cross-sectional analysis in New York. <i>BMJ Open</i> , 2021 , 11, e042965	3	2
192	Therapeutic Strategies in the Management of COVID-19. 2020 , 7, 636738		8
191	Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19. <i>Pathogens</i> , 2021 , 10,	4-5	10
190	Modalities and Mechanisms of Treatment for Coronavirus Disease 2019. 2020 , 11, 583914		4
189	COVID-19 and the generation of novel scientific knowledge: Research questions and study designs. 2021 , 27, 694-707		1
188	Use of Hydroxychloroquine in Patients with COVID-19: A Retrospective Observational Study. 2021 , 22, 62-66		2
187	Content Analysis and Characterization of Medical Tweets During the Early Covid-19 Pandemic. <i>Cureus</i> , 2021 , 13, e13594	1.2	2
186	Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. 2021 , 115, 139-150		10
185	Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. 2021 , 12, 574425		13
184	Surge effects and survival to hospital discharge in critical care patients with COVID-19 during the early pandemic: a cohort study. 2021 , 25, 70		5

183	COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. 2021 , 8, 606755		2
182	Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings. <i>International Journal of Infectious Diseases</i> , 2021 , 104, 250-254	10.5	51
181	The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2. 2021 , 213, 113157		15
180	Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. 2021 , 27, 281-290		8
179	Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020. 2021 , 26,		2
178	Clinical Course and Risk Factors of Disease Deterioration in Critically Ill Patients with COVID-19. 2021 , 32, 310-315		13
177	Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea. <i>International Journal of Infectious Diseases</i> , 2021 , 104, 7-14	10.5	9
176	Renal Manifestations of Covid-19: Physiology and Pathophysiology. 2021 , 10,		9
175	Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. 2021 , 11, 7282		24
174	Does hydroxychloroquine still have any role in the COVID-19 pandemic?. 2021 , 22, 1257-1266		4
173	Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment. 2021 , 12, 635371		21
172	An Overview of the Treatment Options Used for the Management of COVID-19 in Pakistan: Retrospective Observational Study (Preprint).		
171	COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?. 2021 , 13, 259-284		12
170	Factors affecting mortality in geriatric patients hospitalized with COVID-19. 2021 , 51, 454-463		5
169	Cardiac TdP risk stratification modelling of anti-infective compounds including chloroquine and hydroxychloroquine. 2021 , 8, 210235		3
168	System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India. 2021 , 19, 1331-1339		2
167	Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review. 2021 , 17, 371-387		31
166	Timing and dosage may be the key in the realisation of hydroxychloroquine+azithromycin treatment benefit in Covid-19 elderly patients. 2021 , 57, 106314		2

165	Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2. 2021 , 13,		12
164	Hydroxychloroquine+Azithromycin treatment in elderly patients. 2021 , 57, 106313		
163	Practical recommendations for the prevention and management of COVID-19 in low-income and middle-income settings: adapting clinical experience from the field. 2021 , 9,		1
162	The time to offer treatments for COVID-19. 2021 , 30, 505-518		9
161	Confronting the COVID-19 Pandemic: December 2019–May 2020. 1-28		
160	The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. 2021 , 8, 681-691		2
159	Covid-19: predictive mathematical formulae for the number of deaths during lockdown and possible scenarios for the post-lockdown period.. 2021 , 477, 20200745		4
158	Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations. 2021 , 22, 370		0
157	Adapting for the COVID-19 pandemic in Ecuador, a characterization of hospital strategies and patients. <i>PLoS ONE</i> , 2021 , 16, e0251295	3.7	0
156	Asthma in patients with coronavirus disease 2019: A systematic review and meta-analysis. 2021 , 126, 524-534		11
155	Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines. 2021 , 137, 111330		13
154	An Overview of the Treatment Options Used for the Management of COVID-19 in Pakistan: Retrospective Observational Study. 2021 , 7, e28594		5
153	A call to caution when hydroxychloroquine is given to elderly patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2021 , 106, 265-268	10.5	0
152	Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget. 2021 , 8, 645172		1
151	Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. 2021 , 151, 112106		3
150	Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19. 2021 , 17, 319-327		2
149	Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials. 2021 , 115, 456-466		5
148	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. 2021 , 18, 261-270		2

147	Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials. 2021 , 11, 11974		9
146	An Overview of the Epidemiologic, Diagnostic and Treatment Approaches of COVID-19: What do We Know?. 2021 , 42, 1604061		2
145	Coronavirus disease and the cardiovascular system: a narrative review of the mechanisms of injury and management implications. 2021 , 11, 939-953		
144	Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy. <i>PLoS ONE</i> , 2021 , 16, e0251731	3-7	5
143	COVID-19 rhapsody: Rage towards advanced diagnostics and therapeutic strategy. 2021 , 11, 529-540		1
142	Trends in COVID-19 cases and clinical management in Veterans Health Administration medical facilities: A national cohort study. <i>PLoS ONE</i> , 2021 , 16, e0246217	3-7	1
141	Open-label randomized control trial of hydroxychloroquine in patients with moderate to severe coronavirus disease 2019 infection. 2021 , 77, S305-S311		2
140	COVID-19 Severity: Lung-Heart Interplay. 2021 , 17, e230421189016		5
139	Efficacy and Safety of Leflunomide for Refractory COVID-19: A Pilot Study. 2021 , 12, 581833		1
138	Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic. 2021 , 1		3
137	A dossier on COVID-19 chronicle. 2021 ,		2
136	[Potentially useful drugs in the treatment of COVID-19 in Primary Care]. 2021 ,		
135	Teaching math in real time.. 2021 , 1-17		1
134	A critical review on environmental presence of pharmaceutical drugs tested for the covid-19 treatment. 2021 , 152, 568-582		10
133	Therapeutic prospects of mesenchymal stem/stromal cells in COVID-19 associated pulmonary diseases: From bench to bedside. 2021 , 13, 1058-1071		5
132	SARS-CoV-2 and Cystic Fibrosis: Expectations Versus Reality, a Literature Review.		
131	Electrophysiological and Proarrhythmic Effects of Hydroxychloroquine Challenge in Guinea-Pig Hearts. 2021 , 4, 1639-1653		0
130	Peptides of <i>H. sapiens</i> and <i>P. falciparum</i> that are predicted to bind strongly to HLA-A*24:02 and homologous to a SARS-CoV-2 peptide. 2021 , 221, 106013		1

129	Evaluating the effectiveness of control measures in multiple regions during the early phase of the COVID-19 pandemic in 2020. 2021 , 3, 264-275	2
128	Interferon β an enhancer of the innate immune response against SARS-CoV-2 infection. 2021 , 158, 105105	2
127	Keeping Meta-Analyses Hygienic During the COVID-19 Pandemic. 2021 , 9, 722458	0
126	COVID-19 challenges and its therapeutics. 2021 , 142, 112015	14
125	Drugs for the Treatment of COVID-19. 2021 , 193-204	
124	COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. 2021 , 10, 93-113	9
123	Impact of repurposed drugs on the symptomatic COVID-19 patients. 2021 , 14, 24-38	3
122	Addressing Non-linear System Dynamics of Single-Strand RNA Virus-Host Interaction. 2020 , 11, 600254	2
121	Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned. 2021 , 21, 5	4
120	Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets. 2021 , 26,	12
119	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. 2021 , 53, 166-219	11
118	Rationale for azithromycin in COVID-19: an overview of existing evidence. 2021 , 8,	23
117	Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. 2020 , 14, 641-648	97
116	A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. 2020 , 56, 106028	62
115	Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. <i>International Journal of Infectious Diseases</i> , 2020 , 101, 283-289	10.5 24
114	Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review. 2020 , 88, 106942	5
113	Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. 2020 , 75, 363-370	20
112	RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. 2020 ,	464

111	Natural history of COVID-19 and therapeutic options. 2020 , 16, 1159-1184	41
110	Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients. 2020 , 69, 1228-1234	63
109	The Role of Hydroxychloroquine in the Age of COVID-19: A Periodic Systematic Review and Meta-Analysis.	17
108	Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19.	13
107	Kidney Allograft Recipients Diagnosed with Coronavirus Disease-2019: A Single Center Report.	2
106	Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients.	29
105	Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea.	7
104	COVID-19: Predictive Mathematical Models for the Number of Deaths in South Korea, Italy, Spain, France, UK, Germany, and USA.	3
103	Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions.	4
102	Enantiomers of Chloroquine and Hydroxychloroquine Exhibit Different Activities Against SARS-CoV-2 in vitro, Evidencing S-Hydroxychloroquine as a Potentially Superior Drug for COVID-19.	5
101	THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19.	2
100	Pre exposure Hydroxychloroquine Prophylaxis for COVID-19 in healthcare workers: a retrospective cohort.	13
99	Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. 2020 ,	17
98	SARS-CoV-2 Spike protein promotes hyper-inflammatory response that can be ameliorated by Spike-antagonistic peptide and FDA-approved ER stress and MAP kinase inhibitors in vitro.	14
97	Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of 26 studies and 44,521 patients.	2
96	A rationale for targeting the P2X7 receptor in Coronavirus disease 19. 2020 , 177, 4990-4994	36
95	A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. 2020 , 287, 3633-3650	65
94	Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. 2020 , 79, 1007-1013	82

93	Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. 2020 , 37, 9		8
92	COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. 2020 , 5,		200
91	Some opportunities for immunotherapy in coronavirus infection. 2020 , 10, 446-458		9
90	Pharmacological therapies for patients with human coronavirus infections: a rapid systematic review. 2020 , 25, 3517-3554		2
89	[Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "Bromhexine and Spironolactone for Coronavirus Infection requiring hospitalization (BISCUIT)". 2020 , 60, 4-15		7
88	COVID-19 and the quality use of medicines: evidence, risks and fads. 2020 , 43, 78-80		3
87	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. 2020 , 13, 4673-4695		20
86	No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19. 2020 , 1, e19583		1
85	Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review. 2020 , 22, e21758		13
84	Pharmacological treatment of COVID-19: an update.		1
83	Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in Multiple Cell Lines and Tissues by Dynamic Imaging System and Physiologically Based Pharmacokinetic Model. 2020 , 11, 574720		8
82	Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System. 2020 , 9,		4
81	Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence. 2020 , 52, 317-334		6
80	Clinical characteristics, predictors of symptomatic coronavirus disease 2019 and duration of hospitalisation in a cohort of 632 Patients in Lagos State, Nigeria. 2020 , 27, 285-292		3
79	Hydroxychloroquine and Coronavirus Disease 2019: A Systematic Review of a Scientific Failure. 2020 , 11,		6
78	An overview of potential therapeutic agents to treat COVID-19. 2020 , 14, 318-327		4
77	Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. <i>Revista Brasileira De Terapia Intensiva</i> , 2020 , 32, 166-196	1.2	22
76	Overview of the Pathogenesis and Treatment of SARS-CoV-2 for Clinicians: A Comprehensive Literature Review. <i>Cureus</i> , 2020 , 12, e10357	1.2	3

75	Clinical Outcomes of Early Treatment With Doxycycline for 89 High-Risk COVID-19 Patients in Long-Term Care Facilities in New York. <i>Cureus</i> , 2020 , 12, e9658	1.2	22
74	ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review. 2021 , 22,		1
73	Characteristics of Hydroxychloroquine Dispensing in the United States, January to May 2020. 2021 , 1		
72	Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 in health-care workers: A single-center experience. 2020 ,		
71	Covid-19 in Chile. The experience of a Regional reference Center. Preliminary report.		1
70	SARS-CoV-2: The Second Wave in Europe (Preprint).		
69	Treatment of Coronavirus Disease 2019: Shooting in the Dark. 2020 , 15, e59		2
68	Hydroxychloroquin ohne Einfluss auf das Intubations- und Sterberisiko. 2020 , 22, 30-31		
67	SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review. 2021 ,		3
66	Outcomes of COVID-19 Patients Hospitalized at Acute Care Services: Real-World Experience in the New York Metropolitan Area During the Early Pandemic Before Initiation of Clinical Trials. 2021 , 29, e88-e96		
65	Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic. 2021 , 8, ofaa602		3
64	COVID-19 pandemic: Case studies and perspectives. 2020 , 42, 291-297		1
63	Hydroxychloroquine: the story of one drug during the COVID-19 pandemic. 2020 , 123, 74		
62	An Update on Pharmacological Relevance and Chemical Synthesis of Natural Products and Derivatives with Anti SARS-CoV-2 Activity.. <i>ChemistrySelect</i> , 2021 , 6, 11502-11527	1.8	3
61	Identification and Development of Therapeutics for COVID-19. <i>MSystems</i> , 2021 , e0023321	7.6	5
60	The Impact of COVID-19 on Liver Injury: COVID-19 and Liver Injury. <i>American Journal of the Medical Sciences</i> , 2021 ,	2.2	3
59	Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: a meta-review of systematic reviews and an updated meta-analysis.		1
58	COVID-19 in a Rural Health System in New York [Case Series and an Approach to Management.		

57	A Summary of Coronavirus Disease 2019: What We Should Know?. 2020 , 26, S24-S35		
56	Hydroxychloroquine for prevention of COVID-19 mortality: a population-based cohort study.		
55	Hydroxychloroquine (HCQ) reverses anti-PD-1 immune murine checkpoint blockade: TCF1 as a marker in humans for COVID-19 and HCQ therapy.		
54	Treatments for COVID-19: emerging drugs against the coronavirus. <i>Acta Biomedica</i> , 2020 , 91, 118-136	3.2	7
53	A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2021 , 13, 163-171	1.1	1
52	Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance. <i>Journal of Clinical Pharmacology</i> , 2021 ,	2.9	1
51	A Narrative Review of Existing Options for COVID-19-Specific Treatments. <i>Advances in Virology</i> , 2021 , 2021, 8554192	1.9	
50	CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target. <i>Science of the Total Environment</i> , 2021 , 808, 152072	10.2	14
49	Medical Treatment in Covid-19: Changes in Post-treatment Laboratory Results and CT Findings. <i>Mustafa Kemal Üniversitesi Tıp Dergisi</i> ,	0	
48	Negative Nasopharyngeal SARS-CoV-2 PCR Conversion in Response to Different Therapeutic Interventions.. <i>Cureus</i> , 2022 , 14, e21442	1.2	2
47	High-cited favorable studies for COVID-19 treatments ineffective in large trials.		
46	LC-MS/MS Method for Determination of Hydroxychloroquine and Metabolites: Application in a Pharmacokinetic Study.. <i>Journal of Analytical Methods in Chemistry</i> , 2022 , 2022, 6058445	2	0
45	Hydroxychloroquine/Chloroquine for the Treatment of Hospitalized Patients with COVID-19: An Individual Participant Data Meta-Analysis.. 2022 ,		1
44	Hydroxychloroquine/Chloroquine in COVID-19 With Focus on Hospitalized Patients [A Systematic Review.		0
43	Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study.. <i>International Journal of Infectious Diseases</i> , 2021 ,	10.5	0
42	The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment.. <i>Medicina (Lithuania)</i> , 2022 , 58,	3.1	0
41	Biomimetic Alveolus-on-a-Chip for SARS-CoV-2 Infection Recapitulation.. <i>Research</i> , 2022 , 2022, 98191547.8		3
40	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. <i>Current Infectious Disease Reports</i> , 2021 , 23, 28	3.9	2

39	Identification and Development of Therapeutics for COVID-19. 2021 ,		
38	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants.. <i>Pathogens</i> , 2022 , 11,	4.5	4
37	NF- κ B Signaling and Inflammation-Drug Repurposing to Treat Inflammatory Disorders?. <i>Biology</i> , 2022 , 11,	4.9	0
36	Efficacy of repurposed antiviral drugs: Lessons from COVID-19.. <i>Drug Discovery Today</i> , 2022 ,	8.8	2
35	High-cited favorable studies for COVID-19 treatments ineffective in large trials.. <i>Journal of Clinical Epidemiology</i> , 2022 ,	5.7	1
34	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management.. <i>American Journal of Emergency Medicine</i> , 2022 , 56, 158-170	2.9	2
33	Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study.. <i>BMJ Open</i> , 2021 , 11, e050051	3	0
32	Real-world treatment patterns and clinical outcomes for inpatients with COVID-19 in the US from September 2020 to February 2021.. <i>PLoS ONE</i> , 2021 , 16, e0261707	3.7	0
31	Malaria Epidemiology and COVID-19 Pandemic: Are They Interrelated?. <i>OMICS A Journal of Integrative Biology</i> , 2022 , 26, 179-188	3.8	1
30	Data_Sheet_1.docx. 2020 ,		
29	Data_Sheet_1.docx. 2020 ,		
28	Data_Sheet_2.docx. 2020 ,		
27	Image_1.tif. 2020 ,		
26	Image_2.TIF. 2020 ,		
25	Image_3.TIF. 2020 ,		
24	Image_4.TIF. 2020 ,		
23	Table_1.doc. 2020 ,		
22	How COVID-19 changed clinical research strategies: a global survey.. <i>Journal of International Medical Research</i> , 2022 , 50, 3000605221093179	1.4	

21	SARS-COV-2 - the pandemic of the XXI century, clinical manifestations - neurological implications.. <i>Journal of Medicine and Life</i> , 2022 , 15, 319-327	1.5	1
20	A narrative review of antiviral drugs used for COVID-19 pharmacotherapy. 2021 , 13, 163		2
19	Update of the recommendations of the Sociedade Portuguesa de Cuidados Intensivos and the Infection and Sepsis Group for the approach to COVID-19 in Intensive Care Medicine.. <i>Revista Brasileira De Terapia Intensiva</i> , 2022 , 33, 487-536	1.2	
18	Why Trust Raoult? How Social Indicators Inform the Reputations of Experts. <i>Social Epistemology</i> , 2022 , 36, 299-316	0.6	1
17	In-silico study for the screening and preparation of ionic liquid-AVDs conjugate to combat COVID-19 surge.. <i>Journal of Molecular Liquids</i> , 2022 , 359, 119277	6	1
16	Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; The HOPE- Covid-19 Registry.. <i>Anti-Infective Agents</i> , 2022 , 20,	0.6	
15	Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection. <i>World Journal of Experimental Medicine</i> , 2022 , 12, 44-52	0.4	0
14	Journey of Chloroquine/ Hydroxychloroquine in the management of COVID-19. <i>Research Journal of Pharmacology and Pharmacodynamics</i> , 2022 , 110-116	1.7	
13	Drug combination therapies for SARS-CoV-2 (COVID-19) treatment. 2022 , 181-203		
12	Don't Look Up! Your Science Herd Immunity or Herd Mentality?. <i>Microorganisms</i> , 2022 , 10, 1463	4.9	
11	Enhanced Epistemic Trust and the Value-Free Ideal as a Social Indicator of Trust. 2022 , 36, 561-575		0
10	Bacterial co-infections and antimicrobial resistance associated with the Coronavirus Disease 2019 infection. 1-22		0
9	Technical Data of In Silico Analysis of the Interaction of Dietary Flavonoid Compounds against Spike-Glycoprotein and Proteases of SARS-CoV-2. 2022 , 7, 144		0
8	Arzneimittelnutzung unter Pandemiebedingungen. 2022 , 171-187		0
7	Spotlight on 4-substituted quinolines as potential anti-infective agents: Journey beyond chloroquine.		0
6	Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation. 2022 , 20,		0
5	Misinterpretation of statistical nonsignificance as a sign of potential bias: Hydroxychloroquine as a case study. 1-20		0
4	Effectiveness of different treatment regimens on patients with COVID-19, hospitalized in Sanandaj hospitals: a retrospective cohort study. 2023 , 16,		1

- 3 Antimalarial drugs. **2023**, 363-396 ○
- 2 Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. 59, ○
- 1 Phytochemicals of *Withania somnifera* as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. **2023**, 11, 1000 ○